Mersana Therapeutics, Inc. Appoints Andrew A. F. Hack, M.D., Ph. D, to its Board of Directors
January 06, 2017 at 08:00 am EST
Share
Mersana Therapeutics, Inc. announced the appointment of Andrew A. F. Hack, M.D., Ph. D, to its board of directors. Dr. Hack currently serves as Chief Financial Officer at Editas Medicine; a position he has held since 2015. Previously, he served as a portfolio manager at Millennium Management, managing a healthcare investment fund focused on biotechnology, pharmaceutical, and medical device companies. Prior to Millennium, Dr. Hack was a securities analyst at HealthCor Management, Carlyle-Blue Wave Partners, and the MPM BioEquities Fund.
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.